Concentric Capital Strategies’s AbbVie ABBV Stock Holding History

Concentric Capital Strategies’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.72M	Buy	6,825 +1,797	+36%	+$387K	0.1%	187
2026 Q1	$1.09M	Buy	5,028 +2,958	+143%	+$656K	0.09%	145
2025 Q4	$473K	Buy	2,070 +1,091	+111%	+$249K	0.02%	229
2025 Q3	$227K	Sell	979 -1,284	-57%	-$261K	0.01%	292
2025 Q2	$420K	Buy	+2,263	New	+$421K	0.02%	253
2025 Q1	–	Sell	-1,357	Closed	-$241K	–	161
2024 Q4	$241K	Sell	1,357 -7,035	-84%	-$1.29M	0.01%	244
2024 Q3	$1.66M	Buy	8,392 +2,753	+49%	+$514K	0.07%	217
2024 Q2	$967K	Buy	+5,639	New	+$934K	0.05%	249
2023 Q4	–	Sell	-3,423	Closed	-$510K	–	215
2023 Q3	$510K	Buy	+3,423	New	+$503K	0.05%	159
2023 Q2	–	Sell	-11,838	Closed	-$1.89M	–	144
2023 Q1	$1.89M	Buy	+11,838	New	+$1.81M	0.62%	64

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Concentric Capital Strategies's ABBV Position: Q2 2026 in Review

Concentric Capital Strategies increased its AbbVie (ABBV) stake by 36% in Q2 2026, buying an estimated $387K and bringing the position to 6,825 shares worth $1.72M. The position accounts for 0.1% of the portfolio, ranked #187.

Concentric Capital Strategies first reported a position in ABBV in Q1 2023 and has held it in 10 quarters since. The position peaked at $1.89M in Q1 2023. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Concentric Capital Strategies held 6,825 shares of AbbVie worth $1.72M as of Q2 2026.
Concentric Capital Strategies bought 1,797 AbbVie shares in Q2 2026, an estimated $387K.
AbbVie made up 0.1% of Concentric Capital Strategies's portfolio in Q2 2026, its #187 holding.
Concentric Capital Strategies first reported a position in AbbVie in Q1 2023 and has held it in 10 quarters since.
Concentric Capital Strategies's AbbVie position peaked at $1.89M in Q1 2023.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Concentric Capital Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.